U.S., May 17 -- ClinicalTrials.gov registry received information related to the study (NCT06975293) titled 'STC-15 as a Part of Combination Therapy With Toripalimab in Selected Advanced Cancers' on April 14.
Brief Summary: This early phase oncology trial will be conducted at various study centers to investigate the safety, tolerability, and antitumor activity of STC-15 (a METTL3 inhibitor) in combination with toripalimab (anti- programmed cell death 1 [PD-1]) in four different locally advanced unresectable or metastatic tumors such as indications: (1) in combination with toripalimab (anti- programmed cell death 1 [PD-1]) in locally advanced and unresectable or metastatic non-small cell lung cancer (NSCLC), (2) in combination with toripalim...